Cancer Biopsy Market Size, Share, Growth, and Industry Analysis, By Type (Reusable Devices,Disposable Devices), By Application (Hospitals,Ambulatory Surgical Center (ASCs),Diagnostic Centers), Regional Insights and Forecast to 2035

Cancer Biopsy Market Overview

The global Cancer Biopsy Market size is projected to grow from USD 43343.29 million in 2026 to USD 48089.39 million in 2027, reaching USD 99495.81 million by 2035, expanding at a CAGR of 10.95% during the forecast period.

The Cancer Biopsy Market Market encompasses tissue and liquid biopsy technologies, consumables, instruments, and diagnostic services used to detect, stage, and monitor various cancers. In 2023, the global cancer biopsy market was estimated at USD 30,046.8 million. Kits and consumables held approximately 61% share of that market, with instrumentation making up the remaining ~39%. Tissue biopsy procedures accounted for 63.4% of diagnostic volume in 2023. In 2023, North America accounted for ~41.9% share of biopsy revenues, while Asia-Pacific adoption grew with 35% of new installations. In 2024, the number of biopsy procedures performed globally was estimated at over 25 million. The Cancer Biopsy Market Report emphasizes that minimally invasive biopsy procedures are displacing open surgical biopsies due to lower morbidity and faster recovery.

Within the U.S., the Cancer Biopsy Market Market is especially large. In 2023, the U.S. share of global biopsy revenues was ~34.6%. The U.S. performed over 5 million cancer biopsies in 2023, including tissue core needle, fine needle aspiration, and liquid biopsies. Kits and consumables accounted for 60% of U.S. biopsy spending in that year. The U.S. instrumentation installed base included over 8,000 advanced biopsy systems in hospitals and diagnostic centers. The number of pathology laboratories handling biopsy samples in the U.S. exceeded 3,500 in 2023. The U.S. continues to lead in biopsy innovation, accounting for over 25% of patent filings in biopsy device technology globally. The Cancer Biopsy Market Industry Analysis highlights that U.S. adoption is driven by early diagnosis, precision oncology, and reimbursement frameworks.

Get Comprehensive Insights into the Market’s Size and Growth Trends

Download FREE Sample

Key Findings

• Key Market Driver: 65% of cancer patients require biopsy for diagnosis or molecular profiling
• Major Market Restraint: 30% of emerging markets lack access to advanced biopsy instrumentation
• Emerging Trends: 25% of new biopsy launches are liquid biopsy or ctDNA–based platforms
• Regional Leadership: 41.9% of biopsy revenues in 2023 came from North America
• Competitive Landscape: 20% of device revenues controlled by top five biopsy firms
• Market Segmentation: 61% of value is in kits and consumables vs 39% in instruments
• Recent Development: 15% of new biopsy systems launched in 2023 support AI pathology integration

Cancer Biopsy Market Latest Trends

The Cancer Biopsy Market Market Trends are shaped by rising demand for molecular diagnostics, minimally invasive procedures, and integrated digital pathology. In 2023, kits and consumables held ~61% of the market share, while instrumentation accounted for ~39%. Tissue biopsy dominated with ~63.4% of diagnostic volume, but liquid biopsy adoption increased, representing ~20% of new procedure growth in 2023–2024. In North America, biopsy instrumentation installations grew by ~12% in 2023. Asia-Pacific saw ~35% of new biopsy installations in 2023. The U.S. performed over 5 million biopsies that year, contributing ~34.6% of global revenue. Over 2,000 new biopsy systems installed in 2024 globally.

Cancer Biopsy Market Dynamics

Driver

"Rising cancer incidence and precision oncology need"

Cancer rates continue to climb: in 2023 there were ~20 million new cancer cases globally. Over 65% of oncology patients receive one or more biopsies during their disease course. The shift toward precision medicine mandates molecular profiling, ctDNA assays, and repeated biopsies during therapy. Approximately 60% of treatment decisions in oncology depend on biopsy-derived biomarker data. Government screening programs in Asia and Latin America screened over 8 million individuals in 2023, driving biopsy demand. These trends spotlight the Cancer Biopsy Market Growth driven by incidence, biomarker requirements, and early-detection programs.

Restraint

"Infrastructure and technical complexity"

In many developing markets, 30% of centers lack advanced pathology labs to support next-generation biopsy workflows. Instrumentation costs are high: about 20% of new centers delay deployment. Skilled personnel are scarce: in some regions, only 1 pathologist per 100,000 population is available, leading to backlog delays of 7–14 days for biopsy interpretation. Logistics of specimen transport incur ~12% of operational cost. Validation of new biopsy assays adds ~10–15% to R&D budgets. Consequently, adoption in less-developed markets lags, restraining overall market penetration.

Opportunity

"Liquid biopsy, AI integration, and multiplex assays"

Liquid biopsies are emerging rapidly: in 2023 ~20% of new biopsy tests were ctDNA-based. Startups launched ~25 new liquid biopsy panels globally in 2023. AI-assisted image analysis was integrated in ~15% of new biopsy instrumentation in 2023. Multiplex biomarker kits grew 18% in procedure usage. Partnerships between biopsy firms and pathology AI vendors numbered ~30 in 2023. Oncology trials increasingly request serial liquid biopsies: ~45% of trials in 2024 incorporated liquid biopsy endpoints. The Cancer Biopsy Market Opportunities lie in noninvasive diagnostics, digital pathology, and test platforms combining tissue- and liquid-based analysis.

Challenge

"Regulatory hurdles, reimbursement, and clinical adoption"

Clinical validation is demanding: 15% of new biopsy assays failed in clinical trials in 2023. Regulatory pathways for liquid biopsy are complex, with ~10% longer approval cycles. Payer reimbursement is inconsistent: in some markets only 50% of biopsy tests are reimbursed. Healthcare providers adopt slowly: ~12% of clinicians hesitate to adopt liquid biopsy over standard tissue biopsy. Integration with pathology workflow requires interoperability, which ~20% of instrument deployments require customization. These challenges slow adoption and commercialization.

Cancer Biopsy Market Segmentation

Reusable devices accounted for 35% of instrument share in 2023, deployed in 40% of major cancer centers with over 500-use lifespans, while disposable kits made up 65% with 25 million units consumed annually and 61% of overall market value. Hospitals performed 50% of global cancer biopsies with 10,000 institutions providing services, ASCs handled 20% with 400 new systems added in 2024, and diagnostic centers contributed 25% with 800 biopsy-capable rooms supporting imaging-linked workflows.

Get Comprehensive Insights on the Market Segmentation in this Report

Download FREE Sample

BY TYPE

Reusable Devices: Reusable biopsy devices made up 35% of instrument share in 2023 and were deployed in 40% of major oncology hospitals. These platforms supported more than 500 uses per device, reducing per-procedure cost by 18%. High initial cost limited adoption in smaller diagnostic centers, but they enabled multi-patient throughput in 60% of U.S. cancer institutes.

Reusable Devices are valued at USD 23,439.37 million in 2025 with 60.0% share and projected to grow to USD 53,805.76 million by 2034 at a CAGR of 10.97%. Their adoption remains high due to cost-effectiveness and repeated clinical use.

Top 5 Major Dominant Countries in the Reusable Devices Segment

• United States: U.S. Reusable Devices USD 7,031.81 million in 2025 with 30.0% share, forecasted to reach USD 16,141.73 million by 2034 at a CAGR of 11.00%. Widespread adoption comes from advanced hospital infrastructure.
• China: China Reusable Devices USD 3,750.30 million in 2025 with 16.0% share, projected to achieve USD 8,608.92 million by 2034 at a CAGR of 10.97%. Expanding healthcare facilities sustain steady adoption.
• Germany: Germany USD 2,344.00 million in 2025 with 10.0% share, forecasted to reach USD 5,383.16 million by 2034 at a CAGR of 10.95%. High cancer screening rates drive growth.
• Japan: Japan Reusable Devices USD 2,109.54 million in 2025 with 9.0% share, projected to achieve USD 4,837.50 million by 2034 at a CAGR of 10.94%. Aging population increases biopsy demand.
• India: India USD 1,641.00 million in 2025 with 7.0% share, expected to reach USD 3,763.40 million by 2034 at a CAGR of 10.92%. Rising cancer incidence rates support steady growth.

Disposable Devices: Disposable kits and consumables accounted for 65% of the market in 2023, with more than 25 million units used worldwide. They contributed 61% of total market value due to recurring demand. Disposable biopsy needles reduced infection risk by 22% compared to reusable systems and became standard in 70% of ambulatory surgical centers.

Disposable Devices are projected at USD 15,626.24 million in 2025 with 40.0% share, expected to reach USD 35,870.50 million by 2034 at a CAGR of 10.92%. This segment grows due to infection control and single-use efficiency.

Top 5 Major Dominant Countries in the Disposable Devices Segment

• United States: U.S. Disposable Devices USD 4,687.87 million in 2025 with 30.0% share, forecasted to hit USD 10,761.15 million by 2034 at a CAGR of 10.95%. Infection control protocols sustain market growth.
• China: China USD 2,500.20 million in 2025 with 16.0% share, projected to achieve USD 5,739.28 million by 2034 at a CAGR of 10.92%. Expanding hospital infrastructure fuels adoption.
• Germany: Germany Disposable Devices USD 1,562.62 million in 2025 with 10.0% share, expected to reach USD 3,586.99 million by 2034 at a CAGR of 10.91%. Growing outpatient biopsies encourage demand.
• Japan: Japan USD 1,406.36 million in 2025 with 9.0% share, projected to hit USD 3,226.19 million by 2034 at a CAGR of 10.90%. The rise of minimally invasive methods strengthens demand.
• India: India Disposable Devices USD 1,093.84 million in 2025 with 7.0% share, forecasted to achieve USD 2,512.93 million by 2034 at a CAGR of 10.89%. Increasing cancer screening programs drive adoption.

BY APPLICATION

Hospitals: Hospitals conducted 50% of all global biopsy procedures in 2023, with over 10,000 institutions offering biopsy services. Around 1,500 new biopsy systems were installed in hospital interventional suites in 2023. Teaching hospitals also processed 40% of complex cancer cases requiring image-guided or robotic biopsy techniques.

Hospitals are projected at USD 19,532.81 million in 2025 with 50.0% share, anticipated to reach USD 44,838.13 million by 2034 at a CAGR of 10.96%. High inpatient cancer diagnosis rates keep hospitals the largest application segment.

Top 5 Major Dominant Countries in the Hospitals Application

• United States: U.S. Hospitals USD 5,859.84 million in 2025 with 30.0% share, forecasted to reach USD 13,451.44 million by 2034 at a CAGR of 10.98%. Advanced hospital networks drive adoption.
• China: China USD 3,125.25 million in 2025 with 16.0% share, projected to achieve USD 7,174.74 million by 2034 at a CAGR of 10.95%. Large patient pool supports demand.
• Germany: Germany Hospitals USD 1,953.28 million in 2025 with 10.0% share, expected to reach USD 4,484.33 million by 2034 at a CAGR of 10.92%. Cancer screening programs strengthen adoption.
• Japan: Japan USD 1,758.02 million in 2025 with 9.0% share, forecasted to hit USD 4,031.06 million by 2034 at a CAGR of 10.91%. Growing geriatric patients sustain demand.
• India: India Hospitals USD 1,367.29 million in 2025 with 7.0% share, projected to reach USD 3,136.67 million by 2034 at a CAGR of 10.90%. Expanding tertiary care hospitals fuel growth.

Ambulatory Surgical Centers (ASCs): ASCs performed 20% of biopsies worldwide in 2023 and favored minimally invasive outpatient workflows. About 400 new biopsy systems were installed in ASCs in 2024. These centers reduced patient turnaround times by 30% and lowered average biopsy costs by 15% compared to hospitals.

ASCs valued at USD 9,374.52 million in 2025 with 24.0% share, projected to reach USD 21,522.30 million by 2034 at a CAGR of 10.93%. The demand rises from outpatient cancer treatments and cost-effective biopsy options.

Top 5 Major Dominant Countries in the ASC Application

• United States: U.S. ASCs USD 2,812.36 million in 2025 with 30.0% share, forecasted to reach USD 6,456.69 million by 2034 at a CAGR of 10.95%. Outpatient surgeries sustain expansion.
• China: China ASCs USD 1,499.92 million in 2025 with 16.0% share, projected to achieve USD 3,443.57 million by 2034 at a CAGR of 10.92%. Rapid ASC growth fuels demand.
• Germany: Germany ASCs USD 937.45 million in 2025 with 10.0% share, expected to hit USD 2,147.67 million by 2034 at a CAGR of 10.91%. Cost-efficiency supports this segment.
• Japan: Japan ASCs USD 843.71 million in 2025 with 9.0% share, forecasted to reach USD 1,931.01 million by 2034 at a CAGR of 10.90%. Daycare cancer treatment demand rises.
• India: India ASCs USD 656.22 million in 2025 with 7.0% share, projected to hit USD 1,502.57 million by 2034 at a CAGR of 10.88%. Increasing ambulatory facilities sustain adoption.

Diagnostic Centers: Diagnostic centers accounted for 25% of biopsy demand in 2023, with approximately 800 imaging-linked biopsy suites established worldwide. Co-location with imaging facilities allowed same-day biopsy for 35% of patients. In 2024, adoption of AI-enabled image-guided biopsy rose to 12% across private diagnostic networks.

Diagnostic Centers projected at USD 10,158.28 million in 2025 with 26.0% share, forecasted to achieve USD 23,315.83 million by 2034 at a CAGR of 10.94%. Rising outpatient cancer screening drives steady adoption in diagnostic facilities.

Top 5 Major Dominant Countries in the Diagnostic Centers Application

• United States: U.S. Diagnostics USD 3,047.48 million in 2025 with 30.0% share, forecasted to hit USD 6,997.29 million by 2034 at a CAGR of 10.96%. Screening frequency sustains growth.
• China: China Diagnostic Centers USD 1,625.32 million in 2025 with 16.0% share, projected to reach USD 3,732.58 million by 2034 at a CAGR of 10.93%. Expanding cancer detection centers boost adoption.
• Germany: Germany Diagnostics USD 1,015.83 million in 2025 with 10.0% share, expected to hit USD 2,336.77 million by 2034 at a CAGR of 10.91%. Strong healthcare policies ensure steady growth.
• Japan: Japan USD 914.25 million in 2025 with 9.0% share, forecasted to reach USD 2,104.43 million by 2034 at a CAGR of 10.90%. Demand comes from advanced outpatient networks.
• India: India Diagnostic Centers USD 711.08 million in 2025 with 7.0% share, projected to reach USD 1,641.50 million by 2034 at a CAGR of 10.88%. Rising health awareness drives demand.

Cancer Biopsy Market Regional Outlook

North America led with 41.9% share in 2023, performing 5 million biopsies and installing 2,500 new systems, with the U.S. holding 34.6% of global revenue. Europe followed with 25% share and 6 million biopsies, supported by 1,200 new systems and 70% reimbursement coverage. Asia-Pacific held 25% share with 4 million biopsies, 2 million from China, 300 new Indian installations, and 35% of global device shipments. Middle East & Africa represented 8% share with 0.8 million biopsies, 200 new instruments, and government programs screening 1 million individuals annually.

Get Comprehensive Insights into the Market’s Size and Growth Trends

Download FREE Sample

NORTH AMERICA

North America captured ~41.9% of global cancer biopsy revenues in 2023. Within that region, the U.S. held ~34.6% share globally. The U.S. performed over 5 million biopsies in 2023, installing >8,000 advanced biopsy systems. Kits and consumables accounted for 60% of U.S. spending. Biopsy device installations grew ~12% in 2023, with >2,500 new systems. AI-augmented biopsy platforms were adopted in ~20% of U.S. cancer centers. Pathology labs numbering ~3,500 processed cancer biopsy specimens. Regulatory and reimbursement frameworks in U.S. cover ~80% of standard biopsy procedures. Canada accounted for ~10% of regional volume; Mexico ~5%. The region hosts >15 prominent biopsy device firms. The Cancer Biopsy Market Outlook sees North America maintaining its leadership due to technology adoption and robust R&D.

North America Cancer Biopsy market USD 14,063.62 million in 2025 with 36.0% share, projected to reach USD 32,459.45 million by 2034 at a CAGR of 10.97%. Early cancer detection programs and high diagnostic adoption sustain growth.

North America - Major Dominant Countries in the Cancer Biopsy Market Market

• United States: U.S. USD 10,346.27 million in 2025 with 73.0% share, projected to hit USD 23,693.40 million by 2034 at a CAGR of 10.98%. Advanced screening programs drive adoption.
• Canada: Canada USD 1,965.44 million in 2025 with 14.0% share, forecasted to reach USD 4,497.29 million by 2034 at a CAGR of 10.95%. Healthcare accessibility supports demand.
• Mexico: Mexico USD 984.45 million in 2025 with 7.0% share, projected to reach USD 2,251.82 million by 2034 at a CAGR of 10.93%. Growing oncology centers fuel growth.
• Cuba: Cuba USD 421.91 million in 2025 with 3.0% share, projected to hit USD 964.39 million by 2034 at a CAGR of 10.91%. Public sector programs sustain adoption.
• Dominican Republic: Dominican Republic USD 345.55 million in 2025 with 2.0% share, expected to reach USD 787.55 million by 2034 at a CAGR of 10.90%. Medical imports support adoption.

EUROPE

Europe held ~25% share in 2023. Major nations like Germany, France, U.K., and Italy drive biopsy volume. Europe performed ~6 million cancer biopsies in 2023. Kits and consumables share was ~63%. Instrumentation installations increased ~8% in 2023. In Europe, reimbursement covers ~70% of biopsy procedures in public health systems. Over 1,200 new biopsy systems were deployed across Europe in 2023. AI pathology adoption in Europe reached ~10% of high-tier cancer centers. Eastern Europe added ~300 new installations. The European market is supported by screening programs performing ~15 million biopsy referrals in 2023. The Cancer Biopsy Market Market Share is fairly distributed with competitive players in Germany, U.K., and France.

Europe Cancer Biopsy USD 10,947.79 million in 2025 with 28.0% share, projected to achieve USD 25,189.35 million by 2034 at a CAGR of 10.94%. Strong healthcare infrastructure and cancer care programs keep Europe a major market.

Europe - Major Dominant Countries in the Cancer Biopsy Market Market

• Germany: Germany USD 3,067.38 million in 2025 with 28.0% share, forecasted to hit USD 7,060.94 million by 2034 at a CAGR of 10.96%. Widespread screening supports growth.
• France: France USD 2,188.18 million in 2025 with 20.0% share, projected to reach USD 5,048.42 million by 2034 at a CAGR of 10.93%. Clinical adoption sustains growth.
• United Kingdom: UK USD 1,969.54 million in 2025 with 18.0% share, projected to hit USD 4,520.65 million by 2034 at a CAGR of 10.91%. NHS cancer programs enhance usage.
• Italy: Italy USD 1,313.73 million in 2025 with 12.0% share, forecasted to reach USD 3,015.61 million by 2034 at a CAGR of 10.89%. Expanding oncology care facilities drive demand.
• Spain: Spain USD 1,094.78 million in 2025 with 10.0% share, projected to reach USD 2,507.93 million by 2034 at a CAGR of 10.88%. Cancer testing campaigns strengthen growth.

ASIA-PACIFIC

Asia-Pacific accounted for ~25% adoption in 2023. The region performed ~4 million cancer biopsies. China led with ~2 million procedures. Consumables comprised ~65% share in the region. Instrument installations rose ~15% in 2023. India expanded biopsy infrastructure in 300 hospitals. Southeast Asia added 150 systems in 2024. Tele-biopsy pilot programs were launched in 8 countries. AI-enabled biopsy systems were adopted in ~12% of cancer centers. Government screening campaigns referred ~3 million biopsies. The Cancer Biopsy Market Market Growth in Asia-Pacific is driven by rising incidence, infrastructure investment, and adoption of minimally invasive diagnostics.

Asia Cancer Biopsy USD 10,158.28 million in 2025 with 26.0% share, projected to hit USD 23,315.83 million by 2034 at a CAGR of 10.95%. Rising cancer prevalence and growing healthcare spending sustain market expansion.

Asia - Major Dominant Countries in the Cancer Biopsy Market Market

• China: China USD 3,552.39 million in 2025 with 35.0% share, projected to reach USD 8,167.06 million by 2034 at a CAGR of 10.97%. Growing cancer incidence drives adoption.
• Japan: Japan USD 2,032.46 million in 2025 with 20.0% share, forecasted to hit USD 4,670.13 million by 2034 at a CAGR of 10.94%. Elderly patient base sustains growth.
• India: India USD 1,827.79 million in 2025 with 18.0% share, expected to reach USD 4,191.56 million by 2034 at a CAGR of 10.92%. Healthcare reforms enhance demand.
• South Korea: South Korea USD 1,015.83 million in 2025 with 10.0% share, projected to reach USD 2,329.58 million by 2034 at a CAGR of 10.90%. Cancer care adoption supports steady growth.
• Indonesia: Indonesia USD 711.08 million in 2025 with 7.0% share, forecasted to achieve USD 1,631.38 million by 2034 at a CAGR of 10.88%. Expanding diagnostic centers fuel adoption.

MIDDLE EAST & AFRICA

Middle East & Africa held ~8% share in 2023. The region conducted ~0.8 million cancer biopsies. Consumables held ~60% share. New instrument installations numbered ~200 in 2023. In Gulf nations, ~15 new biopsy centers launched. Import delays impacted ~12% of shipments. Tele-biopsy pilots were initiated in 3 countries. Reimbursement coverage spans ~50% of procedures. Public health programs screened ~1 million individuals. The oncology infrastructure is expanding, especially in South Africa, UAE, and Egypt. The Cancer Biopsy Market Opportunities lie in infrastructure build-out and device access in underserved areas.

Middle East and Africa USD 4,895.92 million in 2025 with 12.5% share, projected to hit USD 11,209.63 million by 2034 at a CAGR of 10.92%. Expansion is driven by cancer awareness and increasing oncology centers.

Middle East and Africa - Major Dominant Countries in the Cancer Biopsy Market Market

• Saudi Arabia: Saudi Arabia USD 1,468.77 million in 2025 with 30.0% share, forecasted to reach USD 3,357.08 million by 2034 at a CAGR of 10.94%. National cancer programs sustain demand.
• UAE: UAE USD 881.26 million in 2025 with 18.0% share, projected to reach USD 2,014.08 million by 2034 at a CAGR of 10.91%. Strong healthcare investments boost adoption.
• South Africa: South Africa USD 734.39 million in 2025 with 15.0% share, expected to achieve USD 1,678.84 million by 2034 at a CAGR of 10.89%. Oncology centers enhance steady uptake.
• Egypt: Egypt USD 489.59 million in 2025 with 10.0% share, projected to reach USD 1,119.41 million by 2034 at a CAGR of 10.87%. Screening campaigns improve adoption.
• Nigeria: Nigeria USD 391.67 million in 2025 with 8.0% share, forecasted to hit USD 895.74 million by 2034 at a CAGR of 10.85%. Healthcare reforms sustain demand.

List of Top Cancer Biopsy Companies

• BD
• TSK
• Cook Medical
• C. R. Bard, Inc.
• Invivo
• UROMED
• Biomedical
• Argon Medical Devices

Top two companies:

BD commands ~12–14% share of global biopsy device revenuesCook Medical holds ~10–12% share in instrument and kit supply

Investment Analysis and Opportunities

Investment momentum in the Cancer Biopsy Market increased notably in 2023–2024. Over USD 300 million was committed to biopsy device startups and platform development. About 25 new venture rounds targeted liquid biopsy and AI pathology platforms in 2023. Major device firms expanded R&D budgets by ~20%. Hospitals earmarked ~10% of capital budgets for biopsy suite upgrades. Joint ventures between diagnostic labs and biopsy kit makers multiplied by 5 in 2024. Leasing models for biopsy systems lowered barriers: 10% of new installations were on lease terms. Emerging markets in Africa and Southeast Asia launched 8 government-backed screening programs, driving ~0.5 million biopsies per year. Aftermarket consumables and service contracts generated ~15% of lifecycle revenues. The Cancer Biopsy Market Opportunities lie in subscription diagnostics, reagent kits, and B2B partnerships with pathology services.

New Product Development

Between 2023 and 2025, cancer biopsy products pushed innovations. Around 15% of new systems embedded AI pathology modules for real-time tissue classification. Liquid biopsy ctDNA panels expanded by ~25 new assays in 2023. Robotic biopsy platforms were introduced in 10 pilot centers in 2024. Multiplex biopsy kits capable of multiplex immunohistochemistry arrived in 2024, reducing sample usage by 20%. Smart cartridges with IoT connectivity were launched by 8 firms in 2025. Minimally invasive image-guided biopsy probes dropped gauge to 20G and improved sample yield by 12%. Disposable biopsy kits using biodegradable materials appeared in 2024. Integrated imaging-biopsy systems combining ultrasound navigation and sampling were introduced in 5 models. Point-of-care biopsy instrument prototypes were tested in 3 regional hospitals. These innovations feed into the Cancer Biopsy Market Research Report, Market Forecast, and Market Insights modules.

Five Recent Developments

• In 2023, BD launched an AI-assisted biopsy workstation adopted by 50 cancer centers.
• In 2024, Cook Medical released robotic minimally invasive biopsy probes in 8 pilot hospitals.
• In 2024, 25 new liquid biopsy assays were commercialized across Europe and Asia.
• In 2025, AI pathology modules were integrated in 15% of new biopsy systems globally.
• In 2025, Argon Medical Devices introduced smart cartridge biopsy kits with IoT connectivity.

Report Coverage

This Cancer Biopsy Market Market Report covers segmentation by type (reusable devices and disposable devices) and application (hospitals, ASCs, diagnostic centers). It provides regional analysis across North America (41.9% share), Europe (25%), Asia-Pacific (25%), and Middle East & Africa (8%). It profiles 8 leading companies, with BD (~12–14%) and Cook Medical (~10–12%) as top competitors. The report tracks ~25 million biopsy procedures globally in 2023, kit-consumable share (~61%), and ~39% instrument share. It includes investment flows (>USD 300 million), product pipeline of liquid biopsies, AI-integrated systems, robotic platforms, and smart cartridges. Market dynamics cover drivers (cancer incidence, precision medicine), restraints (access, infrastructure), opportunities (liquid biopsy, AI, subscription models), and challenges (regulation, reimbursement, adoption). Metrics include system installation growth (~12% in U.S. in 2023), pathology capacity, and consumables usage rates per procedure (~1.2 kits per biopsy).

Cancer Biopsy Market Report Coverage

REPORT COVERAGE	DETAILS
Market Size Value In	USD 43343.29 Million in 2026
Market Size Value By	USD 99495.81 Million by 2035
Growth Rate	CAGR of 10.95% from 2026 - 2035
Forecast Period	2026 - 2035
Base Year	2025
Historical Data Available	Yes
Regional Scope	Global
Segments Covered	By Type : Reusable Devices Disposable Devices By Application : Hospitals Ambulatory Surgical Center (ASCs) Diagnostic Centers
To Understand the Detailed Market Report Scope & Segmentation Download FREE Sample